Development trends for human monoclonal antibody therapeutics (Q34623105)

3 August 2017

Development trends for human monoclonal antibody therapeutics (English)

1 reference

3 August 2017

1 reference

1 reference

Aaron L Nelson

1

1 reference

PubMed ID

20811384

3 August 2017

Eugen Dhimolea

series ordinal

2

1 reference

PubMed ID

20811384

3 August 2017

Janice M Reichert

series ordinal

3

1 reference

3 August 2017

3 September 2010

1 reference

Nature Reviews Drug Discovery

3 August 2017

1 reference

3 August 2017

9

1 reference

3 August 2017

767-774

1 reference

3 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd3229

3 August 2017

0 references

cites work

Monoclonal antibodies as innovative therapeutics

1 reference

Monoclonal antibody successes in the clinic

31 March 2020

1 reference

Antibodies to watch in 2010

31 March 2020

1 reference

Human monoclonal antibody production. Current status and future prospects

31 March 2020

1 reference

Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity

31 March 2020

1 reference

Production of autoantibodies by human-human hybridomas

31 March 2020

1 reference

Antibody producing human-human hybridomas. II. Derivation and characterization of an antibody specific for human leukemia cells

31 March 2020

1 reference

Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines

31 March 2020

1 reference

Mining human antibody repertoires

31 March 2020

1 reference

Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies

31 March 2020

1 reference

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

31 March 2020

1 reference

Antiendotoxin antibodies: a dead end?

31 March 2020

1 reference

Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin.

31 March 2020

1 reference

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

31 March 2020

1 reference

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

31 March 2020

1 reference

31 March 2020

1 reference

Use of canakinumab in the cryopyrin-associated periodic syndrome

31 March 2020

1 reference

31 March 2020

1 reference

31 March 2020

1 reference

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

31 March 2020

1 reference

Mechanisms of killing by anti-CD20 monoclonal antibodies.

31 March 2020

1 reference

31 March 2020

1 reference

31 March 2020

1 reference

31 March 2020

1 reference

Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through?

31 March 2020

1 reference

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

31 March 2020

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

Anti-infective monoclonal antibodies: perils and promise of development

31 March 2020

1 reference

Development trends for monoclonal antibody cancer therapeutics.

31 March 2020

1 reference

Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs

31 March 2020

1 reference

Antigen-specific human antibodies from mice comprising four distinct genetic modifications

31 March 2020

1 reference

Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies

31 March 2020

1 reference

Human antibodies from transgenic animals

31 March 2020

1 reference

Phage antibodies: filamentous phage displaying antibody variable domains

31 March 2020

1 reference

Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library

31 March 2020

1 reference

Making antibody fragments using phage display libraries

31 March 2020

1 reference

Minimizing the immunogenicity of protein therapeutics

31 March 2020

1 reference

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

31 March 2020

1 reference

Immunogenicity of protein therapeutics

31 March 2020

1 reference

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

31 March 2020

1 reference

Immunogenicity, efficacy and adverse events of adalimumab in RA patients

31 March 2020

1 reference

Immunogenicity of engineered antibodies

31 March 2020

1 reference

Role of panitumumab in the management of metastatic colorectal cancer

31 March 2020

1 reference

Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature

31 March 2020

1 reference

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

31 March 2020

1 reference

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

31 March 2020

1 reference

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

31 March 2020

1 reference

HAHA--nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology

31 March 2020

1 reference

Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab

31 March 2020

1 reference

Human immunoglobulin allotypes: possible implications for immunogenicity

31 March 2020

1 reference

Factor VIII Inhibitors. Natural autoantibodies and anti-idiotypes

31 March 2020

1 reference

The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders

31 March 2020

1 reference

The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions

31 March 2020

1 reference

A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs

31 March 2020

1 reference

Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20811384

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRD3229

1 reference

3 August 2017

1 reference

PubMed ID

20811384